Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$1.17 - $2.7 $421,200 - $972,000
360,000 Added 60.0%
960,000 $1.74 Million
Q4 2022

Feb 14, 2023

BUY
$2.38 - $3.55 $309,400 - $461,500
130,000 Added 27.66%
600,000 $1.6 Million
Q2 2022

Aug 15, 2022

BUY
$3.03 - $5.32 $666,187 - $1.17 Million
219,864 Added 87.9%
470,000 $1.71 Million
Q1 2022

May 16, 2022

BUY
$4.66 - $7.66 $23,300 - $38,300
5,000 Added 2.04%
250,136 $1.27 Million
Q3 2021

Nov 15, 2021

SELL
$13.62 - $19.48 $136,200 - $194,800
-10,000 Reduced 3.92%
245,136 $3.63 Million
Q2 2021

Aug 16, 2021

BUY
$16.94 - $19.89 $4.32 Million - $5.07 Million
255,136 New
255,136 $3.61 Million

Others Institutions Holding ATAI

About ATAI Life Sciences N.V.


  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $197M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Newtyn Management, LLC Portfolio

Follow Newtyn Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Newtyn Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Newtyn Management, LLC with notifications on news.